US EditionASCO 2025: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
4 Articles
4 Articles
Breast cancer, front-line conjugate antibody slows the disease down
The active substance Camizestrant may delay the progression of hormone-sensitive breast cancer if used in time.
Experts have revealed that a certain diet could slow the progression of cancer. This discovery highlights the potential role of nutrition in the management of the disease and opens up new therapeutic avenues.
ASCO 2025: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
Camizestrant will reach blockbuster status in 2030 with total sales worth $1.1 billion, according to GlobalData’s analyst consensus forecast.The post ASCO 2025: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
